

Supplementary material has been published as submitted. It has not been copyedited, or typeset by Acta Dermato-Venereologica

Table SI. Demographics, characteristics of chronic actinic dermatosis, modalities of dupilumab treatment with response and tolerance in patients reported in the literature, including our case report

Sex/age (y)/ country ^(Ref)	CAD duration	Atopy	MED UVA (J/cm ²) / UVB (mJ/cm ²)	Previous systemic treatment for CAD	Dupilumab treatment modalities	Response to dupilumab (delay)	Follow-up duration	Adverse events
M/54/Canada ⁸	UK	AD	UVA: 5 / UVB: 50	MTX, MMF, AZA, HCQ, apremilast, ciclo	Periodically associated with CS	PR (UK)	UK	Conjunctivitis
F/61/USA ⁷	4 y	UK	UVA: - / UVB: 36 (N>96) / Vis.: -	CS, HCQ, MMF	Monotherapy	PR (1 mo)	10 mo	None
M/76/USA ⁷	1.5 y	UK	UVA: - / UVB: - / Vis.: -	MMF	Monotherapy	PR (1 mo)	4 mo	Facial redness
M/79/USA ⁷	4 y	UK	UVA: 3 (N>18) / UVB: 12 (N>36) / Vis.: -	MMF, MTX, AZA	Monotherapy	PR (1 mo)	26 mo	Conjunctivitis
M/66/USA ⁷	6 y	UK	UVA: - / UVB: - / Vis.: -	MMF	Monotherapy	PR (1 mo)	16 mo	None
M/49/USA ⁷	4 y	UK	UVA: 12 (N>18) / UVB: 48 (N>36) / Vis.: -	CS, MMF	Monotherapy	PR (1 mo)	18 mo	Conjunctivitis
M/45/China ¹³	3 y	None	UVA: 14 (N>40) / UVB<26 (N>40)	CS, MTX, HCQ, ciclo	With ciclo for 2 mo, then spaced to every 4 w	CR (2 mo)	>3 mo	None
M/82/China ¹⁴	10 y	None	UVA: - / UVB: 17.3 (N>40)	HCQ	With HCQ for 2 mo, then monotherapy	CR (16 w)	>16 w	None
M/58/China ¹²	>10 y	AD	UVA: 7 (N>10) UVB: 25 (N>40)	CS, MTX, HCQ	With HCQ	CR (UK)	>16 w	None
M/77/China ¹²	4 y	None	UVA: - / UVB: 15 (N>40)	CS, MTX, AZA, HCQ, MMF	With HCQ	CR (UK)	>20 w	None
M/69/China ¹²	1 y	None	UVA: 3 (N>10) / UVB: 18 (N>40)	HCQ	With HCQ	PR (8 w)	>8 w	None
F/34/China ⁹	2 y	AD	UVA: 51 / UVB: 25.7 (N>40)	CS	Monotherapy		12 w	None
F/48/China ⁹	3 y	AD	UVA: 24.02 / UVB: 21.12 (N>40)	HCQ	With HCQ		12 w	Injection site reaction
F/53/China ⁹	8 y	AR	UVA: 44 / UVB: 13 (N>40)	CS, MTX	Monotherapy		12 w	None
M/39/China ⁹	2 y	None	UVA: 21.34 / UVB: 10.2 (N>40)	HCQ	With HCQ		12 w	None
M/55/China ⁹	1 y	AD	UVA: 18.1 / UVB: 32.6 (N>40)	Ciclo	Monotherapy	W12	12 w	None
M/57/China ⁹	1 y	None	UVA: 13.85 / UVB: 7.7 (N>40)	HCQ	With HCQ		16 w	None
F/46/China ⁹	4 y	None	UVA: 28.6 / UVB: 12.4 (N>40)	HCQ, ciclo, CS	Monotherapy	CR, n=7/16	16 w	None
M/48/China ⁹	4 y	None	UVA: 16 / UVB: 24 (N>40)	Ciclo	With ciclo		16 w	None

M/62/China ⁹	9 y	None	UVA: 46.32 / UVB: 20.9 (N>40)	MTX, CS	Monotherapy	PR, n=6/16	12 w	None
M/48/China ⁹	3 y	None	UVA: 55.5 / UVB: 30.4 (N>40)	Thalidomide	Monotherapy		12 w	None
M/65/China ⁹	4 y	None	UVA: 18.4 / UVB: 10.4 (N>40)	None	Monotherapy	SD, n=3/16	12 w	None
M/57/China ⁹	10 y	None	UVA: 12 / UVB: 19 (N>40)	HCQ	With HCQ		16 w	None
M/65/China ⁹	1 y	None	UVA: 20.1 / UVB: 52.1 (N>40)	HCQ	With HCQ		16 w	None
M/72/China ⁹	2 y	None	UVA: 18 / UVB: 22 (N>40)	ciclo	With HCQ		12 w	None
M/55/China ⁹	3 y	None	UVA: 6.31 / UVB: 17.7 (N>40)	HCQ, CS	With HCQ		12 w	None
M/53/China ⁹	3 y	None	UVA: 9.02 / UVB: 32.1 (N>40)	Thalidomide	With thalidomide		16 w	None
F/54/Spain ¹⁰	3 y	None	UVA: 1.8 / UVB: 71/ Vis.: -	CS, MTX	Monotherapy, spaced to every 4 w after 12 mo	PR (2 mo) UVB: 106 (12 mo)	>12 mo	None
M/60/Ireland ¹¹	4 y	None	UVA: decr. / UVB: 1.8/ Vis.: decr.	MTX, CS, ciclo, AZA	Monotherapy for 8 mo, then associated with MTX 15 mg/w	SD in monotherapy (8 mo) CR with MTX (5 mo)	>13 mo	None
M/85/France (our case)	2 y	None	UVA 15 (N>6) / UVB: 100 (N>200)	HCQ, AZA, ciclo	Monotherapy	CR (3 mo)	>12 mo	None

M: male; F: female; CAD: chronic actinic dermatosis; UK: unknown; y: years; AD: atopic dermatitis; AR: allergic rhinitis; MED: minimal erythematol dose; UV: ultraviolet radiation; Vis.: visible light; -: negative; N: normal; decr.: decreased; MTX: methotrexate; MMF: mycophenolate mofetil; AZA: azathioprine; HCQ: hydroxychloroquine; CS: corticosteroids; ciclo: ciclosporin; mo: months; w: weeks; PR: partial response; CR: complete response; SD: stable disease